BRD4 and Hepatic fibrosis: Moreover, this research lays the groundwork for combining BRD4-targeted therapies, such as JQ1, with conventional treatments such as praziquantel, which could enhance therapeutic efficacy and simultaneously mitigate severe liver fibrosis and other complications associated with chronic schistosomiasis and other parasitic diseases.